- Home
- DBD vs ARQT Comparison
DBD vs ARQT Comparison
Compare DBD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- ARQT
- Stock Information
- Founded
- DBD 1859
- ARQT 2016
- Country
- DBD United States
- ARQT United States
- Employees
- DBD N/A
- ARQT N/A
- Industry
- DBD EDP Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- ARQT Health Care
- Exchange
- DBD Nasdaq
- ARQT Nasdaq
- Market Cap
- DBD 2.1B
- ARQT 2.1B
- IPO Year
- DBD N/A
- ARQT 2020
- Fundamental
- Price
- DBD $61.49
- ARQT $27.65
- Analyst Decision
- DBD Strong Buy
- ARQT Strong Buy
- Analyst Count
- DBD 3
- ARQT 7
- Target Price
- DBD $76.67
- ARQT $22.17
- AVG Volume (30 Days)
- DBD 206.7K
- ARQT 3.1M
- Earning Date
- DBD 11-05-2025
- ARQT 10-28-2025
- Dividend Yield
- DBD N/A
- ARQT N/A
- EPS Growth
- DBD 43573.14
- ARQT N/A
- EPS
- DBD 1.35
- ARQT N/A
- Revenue
- DBD $3,690,400,000.00
- ARQT $317,929,000.00
- Revenue This Year
- DBD $3.09
- ARQT $85.27
- Revenue Next Year
- DBD $2.56
- ARQT $30.70
- P/E Ratio
- DBD $45.56
- ARQT N/A
- Revenue Growth
- DBD N/A
- ARQT 129.21
- 52 Week Low
- DBD $34.88
- ARQT $8.90
- 52 Week High
- DBD $66.28
- ARQT $27.92
- Technical
- Relative Strength Index (RSI)
- DBD 51.73
- ARQT 69.56
- Support Level
- DBD $64.26
- ARQT $22.26
- Resistance Level
- DBD $65.44
- ARQT $24.39
- Average True Range (ATR)
- DBD 2.36
- ARQT 1.49
- MACD
- DBD 0.04
- ARQT 0.11
- Stochastic Oscillator
- DBD 60.12
- ARQT 91.70
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.